Regorafenib in Patients with Refractory Metastatic Pancreatic Cancer: A Phase II Study (RESOUND)

References

• Ferlay J , SoerjomataramI, DikshitRet al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer136(5), E359–E386 (2015).
   PubMed Web of Science ®Google Scholar
• Burris HA 3rd , MooreMJ, AndersenJet al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol.15(6), 2403–2413 (1997).
   PubMed Web of Science ®Google Scholar
• Berlin JD , CatalanoP, ThomasJPet al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group trial E2297. J. Clin. Oncol.20, 3270–3275 (2002).
   PubMed Web of Science ®Google Scholar
• Scheithauer W , SchüllB, Ulrich-PurHet al. Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized Phase II trial. Ann. Oncol.14, 97–104 (2003).
   PubMed Web of Science ®Google Scholar
• Rocha Lima CM , GreenMR, RotcheRet al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J. Clin. Oncol.22, 3776–3783 (2004).
   PubMed Web of Science ®Google Scholar
• Oettle H , RichardsD, RamanathanRKet al. A Phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann. Oncol.16, 1639–1645 (2005).
   PubMed Web of Science ®Google Scholar
• Louvet C , LabiancaR, HammelPet al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD Phase III trial. J. Clin. Oncol.23, 3509–3516 (2005).
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK , LetourneauR, HarkerGet al. Randomized Phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J. Clin. Oncol.24, 4441–4447 (2006).
   PubMed Web of Science ®Google Scholar
• Moore MJ , GoldsteinD, HammJet al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a Phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol.25, 1960–1966 (2007).
   PubMed Web of Science ®Google Scholar
• Heinemann V , QuietzschD, GieselerFet al. Randomized Phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J. Clin. Oncol.24, 3946–3952 (2006).
   PubMed Web of Science ®Google Scholar
• Conroy T , DesseigneF, YchouMet al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med.364, 1817–1825 (2011).
   PubMed Web of Science ®Google Scholar
• Von Hoff DD , ErvinT, ArenaFPet al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med.369, 1691–1703 (2013).
   PubMed Web of Science ®Google Scholar
• Wang-Gillam A , DeanA, ShanYSet al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, Phase III trial. Lancet387, 545–557 (2016).
   PubMed Web of Science ®Google Scholar
• Oettle H , RiessH, StielerJMet al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J. Clin. Oncol.32, 2423–2429 (2014).
   PubMed Web of Science ®Google Scholar
• Buchler P , ReberHA, UllrichAet al. Pancreatic cancer growth is inhibited by blockade of VEGF-RII. Surgery134, 772–782 (2003).
   PubMed Web of Science ®Google Scholar
• Itakura J , IshiwataT, ShenBet al. Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer. Int. J. Cancer85, 27–34 (2000).
   PubMed Web of Science ®Google Scholar
• Masood R , CaiJ, ZhengTet al. Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood98, 1904–1913 (2001).
   PubMed Web of Science ®Google Scholar
• Von Marschall Z , CramerT, HockerMet al. De novo expression of vascular endothelial growth factor in human pancreatic cancer: evidence for an autocrine mitogenic loop. Gastroenterology119, 358–1372 (2000).
   PubMed Web of Science ®Google Scholar
• Solorzano CC , BakerCH, BrunsCJet al. Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Cancer Biother. Radiopharm.16, 359–370 (2001).
   PubMed Web of Science ®Google Scholar
• Itakura J , IshiwataT, FriessHet al. Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin. Cancer Res.3, 1309–1316 (1997).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E , VervenneWL, BennounaJet al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J. Clin. Oncol.27, 2231–2237 (2009).
   PubMed Web of Science ®Google Scholar
• Javle M , YuJ, GarrettCet al. Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a Phase II study. Br. J. Cancer100, 1842–1845 (2009).
   PubMed Web of Science ®Google Scholar
• Kindler HL , NiedzwieckiD, HollisDet al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: Phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J. Clin. Oncol.28, 3617–3622 (2010).
   PubMed Web of Science ®Google Scholar
• Kindler HL , IokaT, RichelDJet al. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised Phase III study. Lancet Oncol.12, 256–262 (2011).
   PubMed Web of Science ®Google Scholar
• Gonçalves A , GilabertM, FrancoisEet al. BAYPAN study: a double-blind Phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. Ann. Oncol.23, 2799–2805 (2012).
   PubMed Web of Science ®Google Scholar
• Bergmann LK , MauteL, HeilGet al. A prospective randomized Phase II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV. Eur. J. Cancer51, 27–36 (2015).
   PubMed Web of Science ®Google Scholar
• Cascinu S , BerardiL, SobreroAet al. Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: a GISCAD randomized Phase II study. Dig. Liver Dis.46, 182–186 (2014).
   PubMedGoogle Scholar
• Wilhelm SM , DumasJ, AdnaneLet al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int. J. Cancer129(1), 245–255 (2011).
   PubMed Web of Science ®Google Scholar
• Wu RY , KongPF, XiaLPet al. Regorafenib promotes antitumor immunity via inhibiting PDL-1 and IDO1 expression in melanoma. Clin. Cancer Res.doi:10.1158/1078-0432.CCR-18-2840 (2019) ( Epub ahead of print).
   Web of Science ®Google Scholar
• Grothey A , Van CutsemE, SobreroAet al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, Phase III trial. Lancet381, 303–312 (2013).
   PubMed Web of Science ®Google Scholar
• Demetri GD , ReichardtP, KangYKet al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumors after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, Phase III trial. Lancet381, 295–302 (2013).
   PubMed Web of Science ®Google Scholar
• Bruix J , QinS, MerlePet al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, Phase III trial. Lancet389, 56–66 (2017).
   PubMed Web of Science ®Google Scholar
• Lombardi G , DeSalvo GL, BrandesAAet al. Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, Phase II trial. Lancet Oncol.20(1), 110–119 (2019).
   PubMed Web of Science ®Google Scholar
• Duffaud F , MirO, Boudou-RouquettePet al. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, Phase II study. Lancet Oncol.20(1), 120–133 (2019).
   PubMed Web of Science ®Google Scholar
• Demols A , BorbathI, VanDen Eynde Met al. Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced (nonresectable) and metastatic biliary tumors: a randomized double-blinded Phase II trial – the REACHIN trial. J. Clin. Oncol.37(Suppl.4), 345 Abstract (2019).
   Web of Science ®Google Scholar
• Fukuoka S , HaraH, TakahashiNet al. Regorafenib plus nivolumab in patients with advanced gastric cancer (GC) or colorectal cancer (CRC): an open-label, dose-finding and dose-expansion Phase Ib trial (REGONIVO, EPOC1603). J. Clin. Oncol.37(Suppl. 15), 2522–2522 (2019).
   Web of Science ®Google Scholar
• Eisenhauer EA , TherasseP, BogaertsJet al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1. 1). Eur. J. Cancer45(2), 228–247 (2009).
   PubMed Web of Science ®Google Scholar
• Mayer B , KarakhanovaS, BauerNet al. A marginal anticancer effect of regorafenib on pancreatic carcinoma cells in vitro, ex vivo, and in vivo. Naunyn Schmiedebergs Arch. Pharmacol.390(11), 1125–1134 (2017).
   PubMed Web of Science ®Google Scholar
• Bush KT , BoichardA, TsigelnyIF. In vitro elucidation of drug combination synergy in treatment of pancreatic ductal adenocarcinoma. Anticancer Res.38(4), 1967–1977 (2018).
   PubMed Web of Science ®Google Scholar
• Salmon JS , HwangJJ, RobinsonMMet al. Phase II study of regorafenib (Reg) in patients with previously treated advanced pancreatic cancer (APC). J. Clin. Oncol.35(Suppl.), e15751 Abstract (2017).
   Google Scholar